Treatment Resources

Overview

The resources below are provided to health systems, health care providers, and support staff participating in ALZ-NET to ensure the highest level of care is provided to patients living with Alzheimer’s disease and related dementias.

Cognitive Assessments

AD8 Screening AssessmentFAQNPI-Q

Functional Activities Questionnaire (FAQ); The Neuropsychiatric Inventory Questionnaire (NPI-Q). ALZ-NET is providing the NPI-Q to you for your clinical use. Any commercial application of the instrument requires separate permission. © J Cummings 1995; all rights reserved. 

Novel FDA Approved Therapies for Alzheimer’s Disease

(listed in alphabetical order)

ADUHELM^®  (aducanumab)

Aducanumab was discontinued on Nov. 1, 2024.

• ADUHELM^® (aducanumab) — FDA Label and MedGuide (revised 02/2023)
• ADUHELM^® (aducanumab) — Appropriate Use Recommendations

KISUNLA™ (donanemab)

• KISUNLA™ (donanemab) — FDA Label and MedGuide (revised 07/2024)

LEQEMBI^® (lecanemab)

• LEQEMBI^® (lecanemab) — FDA Label and MedGuide (revised 07/2023)
• LEQEMBI^® (lecanemab) — Appropriate Use Recommendations
• LEQEMBI^® (lecanemab) — Clinician Toolkit

REXULTI™ (brexpiprazole)

• REXULTI™ (brexipiprazole) - FDA Label and MedGuide (revised 05/2024)

Alzheimer's Association Education Center

The Alzheimer’s Association Education Center provides free education programs to clinicians providing care to individuals with Alzheimer’s Disease and related dementias. Examples of free programs include Effective Communication Strategies and Dementia Conversations: Driving, Doctor Visits, Legal & Financial Planning.